Table 1. Patient and cancer baseline characteristics.
|
wTCF (n=50)
|
wTX (n=56)
|
|||
|---|---|---|---|---|
| Characteristic | No. | % | No. | % |
| Age (years) | ||||
| Mean (standard deviation) | 60.5 (11.5) | 59.1 (10.8) | ||
| Range | 35–82 | 32–79 | ||
| Gender | ||||
| Male | 42 | 84 | 42 | 75 |
| WHO performance status | ||||
| 0 | 21 | 42 | 31 | 55 |
| 1 | 28 | 56 | 23 | 41 |
| 2 | 1 | 2 | 2 | 4 |
| Primary site | ||||
| Oesophagus | 11 | 22 | 20 | 36 |
| Oesophagogastric junction | 13 | 26 | 13 | 23 |
| Gastric | 26 | 52 | 23 | 41 |
| Disease status | ||||
| Local recurrence | 2 | 4 | 5 | 9 |
| Histology | ||||
| Squamous cell carcinoma | 2 | 4 | 9 | 16 |
| Adenocarcinoma | 47 | 94 | 45 | 80 |
| Undifferentiated | 1 | 2 | 2 | 4 |
| Sites of metastasis | ||||
| Nodal | 30 | 61 | 41 | 73 |
| Liver | 25 | 51 | 28 | 50 |
| Pulmonary | 7 | 15 | 15 | 27 |
| Peritoneal | 10 | 20 | 6 | 11 |
| Bone | 5 | 10 | 7 | 13 |
| Number of metastatic organs | ||||
| 1 | 24 | 48 | 21 | 38 |
| 2 | 19 | 38 | 24 | 43 |
| 3 | 3 | 6 | 6 | 11 |
| 4 | 3 | 6 | 5 | 9 |
| RMH prognostic index | ||||
| Good | 12 | 24 | 19 | 34 |
| Moderate | 37 | 74 | 36 | 64 |
| Poor | 1 | 2 | 1 | 2 |
| Received before adjuvant treatment | ||||
| Adjuvant radiotherapy | 2 | 4 | 1 | 2 |
Abbreviations: WHO=World Health Organization; wTCF=weekly docetaxel plus cisplatin and 5-fluorouracil; wTX=weekly docetaxel plus capecitabine.